TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04094363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand, filtered combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand, filtered combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand, filtered combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: CSD1902-11, an electronic nicotine delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: CSD1902-11, an electronic nicotine delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: CSD1902-11, an electronic nicotine delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: CSD1902-11, an electronic nicotine delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1902-21, an electronic nicotine delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1902-21, an electronic nicotine delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1902-21, an electronic nicotine delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1902-21, an electronic nicotine delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: 4mg Nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: 4mg Nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: 4mg Nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: 4mg Nicotine gum
Study: NCT01351545

Intervention type: DRUG
Intervention: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Description: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Study: NCT04168385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication.~\*equivalent to 1140 mcg/kg/day maralixibat
Study: NCT03347877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous osteo-periosteal cylinder graft transplantation
Description: Autologous osteo-periosteal cylinder graft transplantation is a novel treatment for Hepple V osteochondral lesions of the talus.
Study: NCT02319616

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded, daily application to one arm for a period of fourteen (14) days
Study: NCT03347877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous osteochondral graft transplantation
Description: Autologous osteochondral graft transplantation is the most common treatment for Hepple V osteochondral lesions of the talus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autologous osteo-periosteal cylinder graft
Description: Autologous osteo-periosteal cylinder graft is taken from ilium.
Study: NCT01901497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
Study: NCT04336722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odevixibat
Description: Odevixibat is a small molecule and selective inhibitor of IBAT.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to experimental drug (odevixibat).
Study: NCT04204278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monovisc
Description: A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
Study: NCT02751762

Intervention type: OTHER
Intervention: Observation Only
Description: No Intervention

Intervention type: OTHER
Intervention: Observation Only
Description: No Intervention
Study: NCT02662062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 35 mg/m2, IV (in the vein) every week for six weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
Study: NCT03076554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
Study: NCT01651065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Diabetes Education Program
Description: The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.~The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT03670654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Description: The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Muscle stretching
Description: The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
Study: NCT02777047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation Coordinated Care
Description: see above
Study: NCT04607512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaglenastat
Description: glutaminase inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: telaglenastat placebo
Description: matching placebo for telaglenastat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxicin
Description: positive control
Study: NCT02446678

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PillCam ESO2
Description: Capsule endoscopy
Study: NCT04585594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mi Propio Camino (MPC)
Description: The Mi Propio Camino (MPC) intervention will be comprised of four sessions. Session 1 will encompass: the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, introduce MPC personal experience monitoring, and usage the mHealth kit. Subsequently, sessions 2-4 will emphasize the benefits of personal experience monitoring through 1) personal insight (finding what works for them) and 2) empowerment to work with their providers. Session 2 will reinforce this by introducing: synergy between medication and lifestyle, principles of heart-healthy eating and physical activity. Session 3 will incorporate discussion of negative beliefs about medication and patient directed lifestyle learning-rotating stations. Lastly, session 4 will introduce the continuation of personal experience monitoring on their own through the use of behavioral strategies for adherence and provider communication strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)
Description: The HCP intervention will be comprised of four sessions and introduce seven lifestyle strategies (LS) subdivided per these sessions. Session 1 will encompass the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, present specific health threats from high BP, and incorporate LS1: taking control of your medication. Subsequently, sessions 2-4 will reinforce the benefits of taking medications through presenting 1) reduced risk for complications and 2) strategies to remember to take medications. Session 2 will present LS2: eating a well-balanced, low-salt diet and LS3: enjoying regular physical activity. Session 3 will follow with introducing LS4: maintaining a healthy weight and LS5: shaking the salt habit while eating out. Session 4 will present LS6: managing stress and LS7: working together with their doctor followed by a review of strategies they can continue on their own.
Study: NCT01631578

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of an autologous mitochondria to the oocyte.
Description: In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
Study: NCT03260374

Intervention type: DEVICE
Intervention: Electric compound action potential
Description: The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .

Intervention type: DEVICE
Intervention: electric stapedial reflex threshold
Description: electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels

Intervention type: DEVICE
Intervention: electric auditory brain stem response
Description: For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
Study: NCT04122911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: pharmacological
Study: NCT03273452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
Study: NCT02687971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miltefosine
Description: Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
Study: NCT03438279

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT03922529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MACRO-I
Description: MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format \[site transitioning to home\]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
Study: NCT04131322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amgevita 40Mg Solution for Injection
Description: Adalimumab 40Mg Solution for Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HUMIRA 40Mg Solution for Injection
Description: Adalimumab 40Mg Solution for Injection
Study: NCT03004261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor derived cytomegalovirus specific T lymphocytes
Description: donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscarnet
Description: Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
Study: NCT01631578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of an autologous mitochondria to the oocyte.
Description: In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
Study: NCT03295578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized feedback
Description: The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic feedback
Description: The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous glucose monitoring device
Description: This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring device
Description: This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
Study: NCT01291173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate (SPD489)
Description: SPD489-30mg capsules taken once daily for up to 11 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate (SPD489)
Description: SPD489 50mg capsules taken once-daily for up to 11 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate (SPD489)
Description: SPD489 70mg capsule taken once-daily for up to 11 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taken once daily for up to 11 weeks
Study: NCT03507894

Intervention type: BEHAVIORAL
Intervention: Multimodal Exercise Rehabilitation Program
Description: Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
Study: NCT02073994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
Study: NCT00912964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching mirabegron placebo tablets.
Study: NCT01421836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP-guided stent insertion
Description: ERCP guided stent insertion for malignant biliary obstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS guided stent insertion
Description: EUS-guided stent insertion for malignant biliary obstruction
Study: NCT03433794

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol 101 Plus (TM)
Description: It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol 101 Plus (TM)
Description: It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster
Description: Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lilly for Better Health
Description: This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
Study: NCT01035463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous hematopoietic stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT02526563

Intervention type: PROCEDURE
Intervention: ropivicaine
Description: Blood draws to measure serum ropivicaine
Study: NCT01412450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nitinol stent
Description: implantation of one Protégé EverFlex stent